Results 291 to 300 of about 804,384 (336)
Some of the next articles are maybe not open access.
Taxanes in Combined Modality Therapy
2003The taxanes are a relatively new group of plant-derived chemotherapeutic agents that have been studied quite extensively in both preclinical studies and in clinical trials. This group of drugs, which includes paclitaxel (Taxol) and docetaxel (Taxotere), act as mitotic spindle inhibitors through their promotion of microtubule assembly and retardation of
Robert M. MacRae, Hak Choy
openaire +1 more source
Preoperative combined modality therapy for pancreatic cancer
World Journal of Surgery, 1995AbstractCombined modality therapy can be administered prior to surgical resection for patients with operable pancreatic cancer. One important criteria used to select patients for this treatment sequence is the absence of arterial vascular encasement by tumor on thin‐section CT scanning; the absence of peritoneal seeding on surgical staging or ...
T A, Rich, D B, Evans
openaire +2 more sources
Combined modality therapy in the treatment of gynecologic malignancies
Seminars in Oncology, 2003During the last several years, combined modality therapy has become increasingly important in the treatment of several malignancies. This trend holds true in the treatment of the gynecologic malignancies. In this review we examine the evolving role of combined modality therapy in the treatment of patients with cervical, vulvar, endometrial, and ovarian
Mark A, Engleman, William, Small
openaire +2 more sources
Adjuvant combined modality therapy for malignant meningiomas
Journal of Neurosurgery, 1996✓ Malignant meningiomas constitute 10% to 15% of all meningiomas and limited information exists regarding adjuvant treatment of these aggressive primary brain tumors. Fourteen patients (eight men, six women), ranging in age from 28 to 61 years (median 51 years), were prospectively treated for primary malignant meningiomas according to an institutional ...
openaire +2 more sources
Combined-Modality Therapy of Cancer
New England Journal of Medicine, 1985The three major methods of treatment for cancer are surgery, irradiation, and chemotherapy. Each has been shown to have considerable efficacy in the therapy of selected cancers, and each has its ow...
openaire +2 more sources
Survival Outcomes for Combined Modality Therapy for Sinonasal Undifferentiated Carcinoma
Otolaryngology Head & Neck Surgery, 2017Phoebe Kuo +4 more
semanticscholar +1 more source
Combined modality therapy in NSCLC.
Annals of oncology : official journal of the European Society for Medical Oncology, 2001Combined modality treatment has 'come out of age' and increasingly represents standard of care for a rapidly growing number of patients in locally advanced stages of NSCLC. Modern progress of treatment techniques as well as possibilities for supportive interventions will lead to lesser treatment toxicities, better patient's compliance to treatment ...
W, Eberhardt, S, Bildat, S, Korfee
openaire +1 more source
Cancer of the Gastroesophageal Junction: Combined Modality Therapy
Surgical Oncology Clinics of North America, 2006Esophageal cancer, an uncommon, but highly virulent malignancy in the United States, will be responsible for nearly 14,000 deaths in the year 2005. The prognosis for patients who have adenocarcinoma of the distal esophagus and gastroesophageal junction and who are treated with the standard approaches of surgery or combined chemoradiation therapy is ...
openaire +2 more sources
Optimizing combined modality therapy for Hodgkin’s disease
International Journal of Radiation Oncology*Biology*Physics, 2003cured of their Hodgkin’s disease. Of the 20%–25% who do relapse, the majority of these are cured with subsequent salvage programs employing either chemotherapy alone or combined modality therapy. The problem, of course, is what happens beyond 10 years. Patients treated with full-dose subtotal nodal radiotherapy, i.e., doses in the range of 40 Gy, will ...
openaire +2 more sources